We estimate a data-driven signature of de novo Parkinson's disease progression as a sequence of disease events. We show that clinical decline in classic markers precedes grey-matter and white-matter neurodegeneration estimated from T1-weighted MRI and diffusion-weighted MRI. Using only cross-sectional data from the PPMI data set, we show model utility for fine-grained staging/stratification of patients, which holds promise for future clinical applications.
This abstract and the presentation materials are available to members only; a login is required.